Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jos Jonkers

Showing results (1-10 of 271) with videos related to

Pageof 28
Sort By:
Cancer Discovery|June 12, 2012
Tracking evolution of BRCA1-associated breast cancerJos Jonkers
Breast Cancer Research : BCR|November 7, 2012
MEK inhibition as a strategy for targeting residual breast cancer cells with low DUSP4 expressionSven Rottenberg, Jos Jonkers
Nature Reviews. Cancer|May 11, 2002
Conditional mouse models of sporadic cancerJos Jonkers, Anton Berns
Nature Reviews. Cancer|August 25, 2012
The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistancePeter Bouwman, Jos Jonkers
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2013
Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?Peter Bouwman, Jos Jonkers
Cell Cycle (Georgetown, Tex.)|August 30, 2008
Mouse models for BRCA1 associated tumorigenesis: from fundamental insights to preclinical utilityPeter Bouwman, Jos Jonkers
Cancer Cell|December 21, 2004
Oncogene addiction: sometimes a temporary slaveryJos Jonkers, Anton Berns
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|January 1, 2008
Modeling therapy resistance in genetically engineered mouse cancer modelsSven Rottenberg, Jos Jonkers
Expert Review of Anticancer Therapy|August 30, 2007
Treating the genetic make-up of breast cancer: a new fashion?Sabine C Linn, Jos Jonkers
Nature Genetics|January 6, 2026
Insights from three decades of BRCA1/2 modeling in miceJulia-Star Darnold, Jos Jonkers
Pageof 28

Showing results (1-10 of 271) with videos related to

Sort By:
Pageof 28
Cancer Discovery|June 12, 2012
Tracking evolution of BRCA1-associated breast cancerJos Jonkers
Breast Cancer Research : BCR|November 7, 2012
MEK inhibition as a strategy for targeting residual breast cancer cells with low DUSP4 expressionSven Rottenberg, Jos Jonkers
Nature Reviews. Cancer|May 11, 2002
Conditional mouse models of sporadic cancerJos Jonkers, Anton Berns
Nature Reviews. Cancer|August 25, 2012
The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistancePeter Bouwman, Jos Jonkers
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2013
Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?Peter Bouwman, Jos Jonkers
Cell Cycle (Georgetown, Tex.)|August 30, 2008
Mouse models for BRCA1 associated tumorigenesis: from fundamental insights to preclinical utilityPeter Bouwman, Jos Jonkers
Cancer Cell|December 21, 2004
Oncogene addiction: sometimes a temporary slaveryJos Jonkers, Anton Berns
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|January 1, 2008
Modeling therapy resistance in genetically engineered mouse cancer modelsSven Rottenberg, Jos Jonkers
Expert Review of Anticancer Therapy|August 30, 2007
Treating the genetic make-up of breast cancer: a new fashion?Sabine C Linn, Jos Jonkers
Nature Genetics|January 6, 2026
Insights from three decades of BRCA1/2 modeling in miceJulia-Star Darnold, Jos Jonkers
Pageof 28